Innovent Biologics, Inc. (1801.HK)
- PR Newswire
Innovent Presents the Results of the First Phase 3 Study of Mazdutide for Weight Management at the ADA's 84th Scientific Sessions
Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, presents the key results of the first Phase 3 clinical trial of mazdutide in Chinese adults with overweight or obesity (GLORY-1) at the ADA Scientific Sessions 2024.
- PR Newswire
Innovent Announces Mazdutide Demonstrates 80.2% Reduction in Liver Fat Content in Exploratory Analysis of Phase 3 Weight Management GLORY-1 Study at ADA 2024
Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, reports the results of liver fat content from the Phase 3 study of mazdutide in Chinese adults with overweight or obesity (GLORY-1) at the ADA scientific sessions 2024.
- PR Newswire
Innovent Reports Oncology Pipeline Updates at Investor Meeting
Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, provided updates on its oncology pipeline at an investor meeting. At several major international oncology annual meetings this year, Innovent presented clinical data on multiple cancer drug candidates, including 10 oral reports and over 15 poste
